SS-31 (Elamipretide)

SS-31 (Elamipretide) is a 6.0–6.5/10 fit for people using mitochondrial, antioxidant, and cardiovascular as a measured experiment, not a belief-based staple. The best anchors are Zhao C et al. 2026, which reports approval-focused review: Barth syndrome rationale, crossover trial limitations, 168-week extension signal, injection-site reactions, and confirmatory trial requirement, and Birk AV et al. 2013, which reports mechanism paper showing SS-31 binds cardiolipin, protects cristae membranes, and accelerates ATP recovery after ischemia in preclinical kidney models. That gives SS-31 (Elamipretide) a real signal, but the report should stay narrow because responder fit, baseline status, and outcome tracking drive the practical value. Use SS-31 (Elamipretide) when the target is specific, measurable, and worth the tradeoff. Skip or stop SS-31 (Elamipretide) when the expected symptom, lab, or performance marker stays flat.

✅ Best for: Diagnosed Barth syndrome patients who qualify for prescription Forzinity, weigh at least 30 kg, and have specialist monitoring. Adults with genetically confirmed mitochondrial disease who can enroll in trials or access legitimate prescription-grade channels. Older adults with objective mitochondrial impairment, low ATPmax on 31P-MRS, low VO2max, sarcopenia, post-viral mitochondrial dysfunction, or similar markers who have already optimized lower-friction mitochondrial basics. Peptide-literate self-experimenters who understand that Karaa 2023 was negative for broad PMM and that FDA approval is Barth-specific.

❌ Avoid if: You are healthy and chasing generalized anti-aging without documented mitochondrial dysfunction. You would source from unverified research-chemical vendors without third-party identity, purity, and sterility data. You cannot tolerate daily subcutaneous injection, rotating sites, refrigeration, sharps, or the high injection-site-reaction burden. You are pregnant, nursing, under 30 kg, dealing with serious hypersensitivity history, working up peripheral neuropathy, or have severe renal impairment without clinician dosing support. Competitive athletes should verify status with GlobalDRO or their anti-doping authority and obtain medical/TUE guidance before use. Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.